Skip to main content

Pardes Biosciences, Inc.

PRDSDelisted Aug 31, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001822711

Pardes Biosciences, Inc. was delisted on Aug 31, 2023; its insiders filed their last Form 4 on Aug 31, 2023; 59 institutions reported holding it in 13F filings for Q2 2023, worth $63.9M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Pardes Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Pardes Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Pardes Biosciences, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Tananbaum James B.President and CEO1,000IndirectAug 31, 20230
Foresite Capital Fund V, L.P.10% Owner1,000IndirectAug 31, 20230
Foresite Capital Opportunity Fund V, L.P.10% Owner1,000IndirectAug 31, 20230
Foresite Capital Management V, LLC10% Owner1,000IndirectAug 31, 20230
Foresite Capital Opportunity Management V, LLC10% Owner1,000IndirectAug 31, 20230
FS Development Holdings II, LLC10% Owner1,000IndirectAug 31, 20230
Auerbach MarkDirector0Aug 31, 20230
Lobell J JayDirector0IndirectAug 31, 20230
Wiggans Thomas GChief Executive Officer0Aug 31, 20230
Henson HeidiChief Financial Officer0Aug 31, 20230
Pottage John C JrDirector–Aug 31, 20230
Smaldone Alsup LaurieDirector–Aug 31, 20230
Lopatin Uri ADirector0IndirectAug 31, 20230
Varney Michael DavidDirector0Aug 31, 20230
Hamill LauraDirector–Aug 31, 20230
Autor Deborah M.Director–Aug 31, 20230
Lacy Elizabeth H.General Counsel, Secretary0Aug 31, 20230
Brusky Sean P.Chief Commercial Officer21,000Feb 3, 20230
Kearney BrianChief Development Officer–Feb 3, 20230
Tinmouth Brian PhilippeChief Bus. & Strategy Officer–Sep 16, 20220
Arnold Lee DChief Scientific Officer–Feb 2, 20220
Pakianathan DeepikaDirector30,000Dec 30, 20210
Hughes OwenDirector30,000Dec 30, 20210
Dubin DanielDirector30,000Dec 30, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 6, 2023 (view filing)9:08 PM ETApr 51 dayTananbaum James B. and 2 othersDirector, 10% OwnerPPurchase+774.0K$1.50+$1.16M+9.7%8.77M after
Apr 6, 2023 (view filing)9:08 PM ETApr 51 dayTananbaum James B. and 2 othersDirector, 10% OwnerPPurchase+774.0K$1.50+$1.16M+6.0%13.6M after
Dec 12, 2022 (view filing)Dec 84 daysBrusky Sean P.Chief Commercial OfficerPPurchase+21.0K$1.19+$25.0KNew position21.0K after
Dec 7, 2022 (view filing)Dec 52 daysWiggans Thomas GChief Executive OfficerPPurchase+12.5K$1.09+$13.6K+33.3%50.0K after
Dec 5, 2022 (view filing)4:24 PM ETDec 14 daysTananbaum James B. and 2 othersDirector, 10% OwnerPPurchase+637.4K$0.85+$541.8K+5.2%12.8M after
Dec 5, 2022 (view filing)Dec 1-24 daysWiggans Thomas GChief Executive OfficerPPurchase+37.5K$1.05+$39.4KNew position37.5K after2 lots
Dec 23, 2021 (view filing)4:52 PM ETDec 221 dayTananbaum James B. and 4 othersDirector, 10% OwnerPPurchase+325.0K$10.00+$3.25MNew position325.0K after